Shares of Biogen (NASDAQ: BIIB) have been volatile in the past few years, largely hinging on success of the company's Alzheimer's treatments. And that's largely because Biogen needs a blockbuster treatment to rally around. Sales in recent years have been declining, and the loss of patent protection for top-selling multiple sclerosis treatment Tecfidera is only exacerbating those concerns.

What will the company's business look like over the next five years, and is it promising enough for investors to buy shares of Biogen today?

When it comes to biotechs, every company needs a solid treatment that the business can build around -- and that can rally investors. Biogen had high hopes for Alzheimer's treatment Aduhelm but it looks to be a flop, failing to get health officials on board, and even Medicare won't cover it unless patients are using it as part of a clinical trial.

Continue reading

Source Fool.com